New combo pill shows promise for type 2 diabetes in japanese patients
NCT ID NCT00974090
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding teneligliptin to standard sulfonylurea therapy improves blood sugar control in 194 Japanese adults with type 2 diabetes. Participants received either teneligliptin or a placebo for 12 weeks, followed by an open-label extension for up to 52 weeks. The main goal was to measure changes in HbA1c, a key marker of long-term blood sugar levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teneligliptin (a DPP-4 inhibitor) combined with sulfonylurea
What this could lead to
If successful, this could provide a new combination option to help people with type 2 diabetes better control their blood sugar levels.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all populations. As with any diabetes medication, there are risks of low blood sugar and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Sapporo, Hokkaido, Japan